AIM: Bioartificial liver is a hope of supporting liver functions in acute liver failure patients. Using polysulfon fibers, a new bioartificial liver was developed. The aim of this study was to show whether this bioartificial liver could support liver functions or not. METHODS: Hepatocytes were procured from swine using Seglen's methods. The bioartificial liver was constructed by polysulfon bioreactor and more than 10(10) hepatocytes. It was applied 14 times in 12 patients, who were divided into 7 cases of simultaneous HBAL and 5 cases of non-simultaneous HBAL. Each BAL treatment lasted 6 hours. The general condition of the patients and the biochemical indexes were studied. RESULTS: After treatment with bioartificial liver, blood ammonia, prothrombin time and total bilirubin showed significant decrease. 2 days later, blood ammonia still showed improvment. within one month period, 1 case (1/7) in simultaneous group died while in non-simultaneous group 2 cases (2/5) died. The difference was significant. Mortality rate was 25 %. CONCLUSION: The constructed bioartificial liver can support liver functions in acute liver failure. The simultaneous HBAL is better than non-simultaneous HBAL.
AIM: Bioartificial liver is a hope of supporting liver functions in acute liver failurepatients. Using polysulfon fibers, a new bioartificial liver was developed. The aim of this study was to show whether this bioartificial liver could support liver functions or not. METHODS: Hepatocytes were procured from swine using Seglen's methods. The bioartificial liver was constructed by polysulfon bioreactor and more than 10(10) hepatocytes. It was applied 14 times in 12 patients, who were divided into 7 cases of simultaneous HBAL and 5 cases of non-simultaneous HBAL. Each BAL treatment lasted 6 hours. The general condition of the patients and the biochemical indexes were studied. RESULTS: After treatment with bioartificial liver, blood ammonia, prothrombin time and total bilirubin showed significant decrease. 2 days later, blood ammonia still showed improvment. within one month period, 1 case (1/7) in simultaneous group died while in non-simultaneous group 2 cases (2/5) died. The difference was significant. Mortality rate was 25 %. CONCLUSION: The constructed bioartificial liver can support liver functions in acute liver failure. The simultaneous HBAL is better than non-simultaneous HBAL.
Authors: J E Everhart; M Lombardero; K M Detre; R K Zetterman; R H Wiesner; J R Lake; J H Hoofnagle Journal: Transplantation Date: 1997-11-15 Impact factor: 4.939
Authors: L M Flendrig; J W la Soe; G G Jörning; A Steenbeek; O T Karlsen; W M Bovée; N C Ladiges; A A te Velde; R A Chamuleau Journal: J Hepatol Date: 1997-06 Impact factor: 25.083
Authors: J C Emond; P F Whitington; J R Thistlethwaite; D Cherqui; E A Alonso; I S Woodle; P Vogelbach; S M Busse-Henry; A R Zucker; C E Broelsch Journal: Ann Surg Date: 1990-07 Impact factor: 12.969
Authors: J Rozga; F Williams; M S Ro; D F Neuzil; T D Giorgio; G Backfisch; A D Moscioni; R Hakim; A A Demetriou Journal: Hepatology Date: 1993-02 Impact factor: 17.425
Authors: Maarten Paul van de Kerkhove; Ruurdtje Hoekstra; Robert A F M Chamuleau; Thomas M van Gulik Journal: Ann Surg Date: 2004-08 Impact factor: 12.969